GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer

Inclusion Criteria: * age 16-65 * histologically confirmed unilateral primary invasive breast cancer * Tumor size≥2cm, axillary lymph node positive, treated with neoadjuvant therapy * complete clinical and histo-pathological information * ECOG 0-1 within 10 days from the beginning of the study * Normal Bone Marrow Reserve: White blood cell count ≥ 3.0×10\^9/L, Neutrophil count ≥ 1.5×10\^9/L, Hemoglobin level ≥ 90g/L; Platelet count (PLT) ≥ 80×10\^9/L; Normal Liver and Kidney Function: Blood aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal, Total bilirubin ≤ 1.5 times the upper limit of normal, Serum creatinine ≤ 1.5 times the upper limit of normal, and Creatinine clearance rate \> 50ml/min. * The patient has good compliance with the planned treatment, understands the research procedures, and has signed a written informed consent form Exclusion Criteria: * bilateral or metastatic (stage IV) breast cancer * There has been a history of other malignancies within the past 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer * Severe systemic infection or other uncontrolled diseases * Patients with psychiatric disorders or those unable to comply with treatment due to other reasons * Known allergy or intolerance to the drug or its excipients * Having received cytotoxic chemotherapy, endocrine therapy, biological therapy, or radiotherapy for any reason in the past * Patients who are pregnant or lactating, as well as patients of reproductive age who refuse to take appropriate contraceptive measures during the course of this trial. * Patients deemed unsuitable for participation in this study by the investigator.